DOSAGE INDEX / SINGLE
Tesamorelin
Research, reported schedules and supply planning.
Understand tesamorelin evidence for HIV-associated abdominal fat, liver research, hormone findings, safety limits and formulation differences.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 1 mg per day initially, then 2 mg per day in the source
- Frequency
- Once daily
- Cycle / observation period
- 12–26 weeks; source also discusses longer studies
- Route / research model
- Subcutaneous
This is not the EGRIFTA WR dose. Tesamorelin products are formulation-specific; see the separate evidence summary.
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–7 | 1 mg | Daily |
| Days 8–84 | 2 mg | Daily |
Compare the product label or clinical-study schedule
Adults with HIV-associated lipodystrophy and excess abdominal fat; EGRIFTA WR formulation.
The EGRIFTA WR label specifies 1.28 mg subcutaneously once daily. EGRIFTA WR and EGRIFTA SV are not substitutable. The indication is not general weight-loss management.
The label contraindicates use with active malignancy, disrupted hypothalamic-pituitary function, hypersensitivity or pregnancy. IGF-1, glucose and treatment response require clinical monitoring.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
EGRIFTA WR uses only its supplied bacteriostatic water. Other tesamorelin formulations need their own instructions; the WR preparation must not be transferred to a research vial.
Vial comparison
Source example: 84-day planning window: 161 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 5 mg | 33 |
| 10 mg | 17 |
| 20 mg | 9 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 2007 randomized trial assigned 412 participants with HIV and abdominal fat accumulation to tesamorelin or placebo for 26 weeks. Computed tomography measured the primary visceral-adipose-tissue endpoint. Visceral fat decreased by 15.2% with tesamorelin and increased by 5.0% with placebo. IGF-I increased by 81.0% versus a 5.0% decrease. More tesamorelin participants withdrew because of adverse events. [1]
- A second randomized study included 404 participants with HIV and excess abdominal fat. At six months, visceral fat decreased by 10.9% with tesamorelin versus 0.6% with placebo. No change was reported in limb or abdominal subcutaneous fat. Participants continuing treatment maintained a reduction through 12 months, while the initial visceral-fat improvement was rapidly lost after switching to placebo. [2]
- A randomized 20-week study included 152 older adults, some with mild cognitive impairment. It reported a favorable overall cognitive result and an executive-function signal with tesamorelin; the verbal-memory analysis showed a nonsignificant trend. Mild adverse events were reported by 68% of treated participants versus 36% receiving placebo. [3]
- The EGRIFTA WR label contraindicates use with active malignancy, disruption of the hypothalamic-pituitary axis, relevant hypersensitivity or pregnancy. It warns about elevated IGF-I, fluid retention, glucose intolerance or diabetes, and requires glucose evaluation before and during treatment. [4]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 39 entries mapped from 3 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original pivotal trial
- Original trial and extension
- Original cognitive trial
- Current prescribing information
- Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver InjuryFurther reading · Listed in reference bibliography.
- Tesamorelin (Subcutaneous route) – Drug InformationGeneral guidance · Listed in reference bibliography.
- Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trialsFurther reading · Listed in reference bibliography.
- Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trialFurther reading · Listed in reference bibliography.
- Tesamorelin can improve cognitive function (Research Highlight)Further reading · Listed in reference bibliography.
- Tesamorelin Injection – MedlinePlus Drug InformationGeneral guidance · Listed in reference bibliography.
- EGRIFTA SV (tesamorelin) – Full Prescribing InformationNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- Tesamorelin: Uses, Dosage, Side Effects, WarningsFurther reading · Listed in reference bibliography.
- Administration of Parenteral Medications – Nursing Skills (Open RN Textbook)Further reading · Listed in reference bibliography.
- EGRIFTA SV Prescribing Information : Official DailyMed label with the 2 mg vial, supplied sterile water, 4 mg/mL concentration, 1.4 mg daily dose, and immediate-use handling.Regulatory / product information · Listed in reference bibliography.
Product-label / dose evidence
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.